News | Cardio-oncology | September 26, 2017

Treatment of Heart Attack Patients Depends on Cancer History

Cancer patients received less recommended drugs and interventions for myocardial infarction and were more likely to die

Treatment of Heart Attack Patients Depends on Cancer History

September 26, 2017 — Treatment of heart attack patients depends on their history of cancer, according to research published recently in European Heart Journal: Acute Cardiovascular Care.1 The study in more than 35,000 heart attack patients found they were less likely to receive recommended drugs and interventions, and more likely to die in hospital if they had cancer than if they did not.

“It is well known that cancer patients may have an increased risk of cardiovascular disease as a result of their treatment,” said senior author Dragana Radovanovic, M.D., head of the AMIS Plus Data Centre in Zurich, Switzerland. “However, on the other hand, little is known about the treatment and outcomes of cancer patients who have an acute myocardial infarction.”

This study investigated whether acute myocardial infarction patients with a history of cancer received the same guideline recommended treatment and had the same in-hospital outcomes as those without cancer.

The study included 35,249 patients enrolled in the acute myocardial infarction in Switzerland (AMIS Plus) registry between 2002 and mid-2015. Of those, 1,981 (5.6 percent) had a history of cancer.

Propensity score matching was used to create two groups of 1,981 patients each — one with cancer history and one without — that were matched for age, gender and cardiovascular risk factors.

The researchers compared the proportions of patients in each group who received specific immediate drug therapies for acute myocardial infarction, and percutaneous coronary intervention (PCI) to open blocked arteries. They also compared the rates of in-hospital complications and death between the two groups.

The researchers found that cancer patients underwent PCI less frequently (odds ratio [OR], 0.76; 95% confidence interval [CI], 0.67–0.88) and received P2Y12 blockers (OR, 0.82; 95% CI 0.71–0.94) and statins (OR, 0.87; 95% CI, 0.76–0.99) less frequently. In-hospital mortality was significantly higher in patients with cancer than those without (10.7% versus 7.6%; OR, 1.45; 95% CI, 1.17–1.81).

Patients with a history of cancer were more likely to have complications while in hospital. They had 44 percent higher odds of cardiogenic shock, 47 percent higher chance of bleeding, and 67 percent greater odds of developing heart failure than those with no history of cancer.

Radovanovic said: “Patients with a history of cancer were less likely to receive evidence-based treatments for myocardial infarction. They were 24 percent less likely to undergo PCI, 18 percent less likely to receive P2Y12 antagonists and 13 percent less likely to receive statins. They had also more complications and were 45 percent more likely to die while in hospital.”

“More research is needed to find out why cancer patients receive suboptimal treatment for myocardial infarction and have poorer outcomes,” continued Radovanovic.

“Possible reasons could be the type and stage of cancer, or severe comorbidities. Some cancer patients may have a very limited life expectancy and refuse treatment for myocardial infarction,” she added.

For more information: www.journals.sagepub.com

 

References

1. Rohrmann S, Witassek F, Erne P, Rickli H, Radovanovic D. Treatment of patients with myocardial infarction depends on history of cancer. European Heart Journal: Acute Cardiovascular Care. 2017. DOI: 10.1177/2048872617729636

Related Content

Beta Blocker Shows Mixed Results in Protecting Against Chemo-Induced Heart Damage
News | Cardio-oncology | March 14, 2018
After six months of follow-up, women newly diagnosed with breast cancer who were given the beta blocker carvedilol to...
Popular Heart Medications Can Prevent Herceptin-Induced Heart Issues in Some Patients,

Image courtesy of Maya Guglin, M.D., Ph.D., University of Kentucky

News | Cardio-oncology | March 14, 2018
March 14, 2018 — Breast cancer p
Heart Failure More Likely for Some Breast Cancer and Lymphoma Survivors
News | Cardio-oncology | March 01, 2018
March 1, 2018 –  Patients who were treated for breast cancer or lymphoma are more than three times at risk for develo
Cell phone emissions cause cardiac tumors in males rats.
News | Cardio-oncology | February 06, 2018
High exposure to radiofrequency radiation (RFR) in rodents resulted in tumors in tissues surrounding nerves in the...
Videos | Cardio-oncology | February 01, 2018
American Heart Association (AHA) released a scientific statement Feb.
Laxmi Mehta, M.D., reviews an echocardiogram at The Ohio State Wexner Medical Center for a cardio-oncology cancer patient to look for heart damage caused by chemotherapy or radiation therapy.

Laxmi Mehta, M.D., reviews an echocardiogram at The Ohio State Wexner Medical Center. She is calling for more research and collaboration to examine the link between heart disease and breast cancer to develop new treatments and preventative measures.

Feature | Cardio-oncology | February 01, 2018
February 1, 2018 – Heart disease and breast cancer are two of the most prevalent diseases among women in the United S
Pediatric echo protocols for cardio-oncology cardiotoxicity exams.
News | Cardio-oncology | June 15, 2017
 June 15, 2017 – Children who have suffered from cancer may also have lasting side effects from the drugs used in the
Strain Imaging Improves Cardiac Surveillance of Certain Breast Cancer Patients
News | Cardio-oncology | May 03, 2017
Epsilon Imaging Inc. announced a research study using EchoInsight was presented at the American College of Cardiology (...
prostate cancer, hormone therapy, cardiac risk factors, Yale Cancer Center study, ASTRO 2016
News | Cardio-oncology | September 28, 2016
September 28, 2016 — In a recent study, a Yale Cancer Center team determined that men who received hormonal therapy f
Overlay Init